Recent Updates
Recently added Catalysts

Divalproex

Phase 3

Bipolar I Disorder | Small molecule | Psychiatry |Abbott Laboratories|Last Updated: Jul 2, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment227
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00195780A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and AdolescentsPHASE3 COMPLETED 227Feb 1, 2005 -Jul 2, 200729 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety
Secondary Endpoints
Y-MRS
CGI-S
C-GAS
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
Divalproex Sodium (Depakote ER)DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range10 Years — 17 Years
SexALL
Healthy VolunteersNo
Study Sites29

Inclusion Criteria: * Subject is between 10 and 17 years of age, inclusive, on Day 1 and weighs at least 60 lbs (27 kg). * Subject has a current psychiatric diagnosis of bipolar I disorder, manic or mixed episode, based on the K-SAD-PL interview and DSM-IV-TR criteria. * Subject is an outpatient in...

Countries:United States
Unlock Eligibility Criteria